September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Chronic manifestations of Vogt-Koyanagi-Harada disease
Author Affiliations & Notes
  • On-Tat Lee
    Ophthalmology, USC Eye Institute, Los Angeles, California, United States
  • Hassan A Aziz
    Ophthalmology, USC Eye Institute, Los Angeles, California, United States
  • Jeffery Tan
    Ophthalmology, USC Eye Institute, Los Angeles, California, United States
  • Jesse L Berry
    Ophthalmology, USC Eye Institute, Los Angeles, California, United States
  • Damien C Rodger
    Ophthalmology, USC Eye Institute, Los Angeles, California, United States
  • Narsing A Rao
    Ophthalmology, USC Eye Institute, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   On-Tat Lee, None; Hassan Aziz, None; Jeffery Tan, None; Jesse Berry, None; Damien Rodger, None; Narsing Rao, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4136. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      On-Tat Lee, Hassan A Aziz, Jeffery Tan, Jesse L Berry, Damien C Rodger, Narsing A Rao; Chronic manifestations of Vogt-Koyanagi-Harada disease. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4136.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the clinical findings in chronic Vogt-Koyanagi-Harada (VKH) disease patients.

Methods :
The current study is a consecutive, comparative case series. The ocular history, medication history and clinical findings of 17 patients clinically diagnosed with chronic VKH at the Los Angeles County + USC Medical Center who were seen during a 2 month period were reviewed.

Results :
Of the 17 patients, 70.6% were female and 100% were Hispanic. The mean age during their last clinical exam was (40.5) years (range, 21-65). Among the 34 eyes, persistently active disease was seen in (35.3%) and quiescent disease was seen in (64.7%). 8.8% of the tested eyes had a visual acuity less or equal to 20/200. The majority of patients were on systemic immunosuppressant medications: 88.2% were on oral corticosteroids and 52.9% were on systemic corticosteroids plus one or more steroid sparing agents (azathioprine, cyclosporine, infliximab, methotrexate or mycophenolate). Ocular manifestations included: chronic anterior uveitis (14.7%), chronic posterior uveitis (14.7%), serous retinal detachment (5.9%), fundus depigmentation (64.7%), nummular scars (58.8%), and retinal pigment epithelium clumping (70.6%). Other findings (on presentation or previously surgical treated) included: cataracts (82.4%) glaucoma (35.3%), choroidal neovascular membranes in (11.8%), and subretinal fibrosis (20.6%).

Conclusions : In the current study, all VKH patients were of Hispanic ethnicity with a female predominance. Most patients were undergoing treatment with a combination of systemic corticosteroids with immunomodulatory/corticosteroid sparing agents. Despite chronic complications, most patients retained good visual acuity of 20/100 or better with combination of corticosteroids and steroid sparing agents.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×